An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination
Science Translational Medicine · 2023
DOI: 10.1126/scitranslmed.abo2847 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2023. Verfasst von Juan Manuel Carreño und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USA. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
NDV-HXP-S is a recombinant Newcastle disease virus–based vaccine against SARS-CoV-2, which expresses an optimized (HexaPro) spike protein on its surface. The vaccine can be produced in embryonated chicken eggs using the same process as that used for the production of the vast majority of influenza virus vaccines. Here, we performed a secondary analysis of the antibody responses after vaccination with inactivated NDV-HXP-S in a phase 1 clinical study in Thailand. The SARS-CoV-2 neutralizing and spike protein binding activity of NDV-HXP-S postvaccination serum samples was compared to that of samples from mRNA BNT162b2 (Pfizer) vaccinees. Neutralizing activity of sera from NDV-HXP-S vaccinees was comparable to that of BNT162b2 vaccinees, whereas spike protein binding activity of the NDV-HXP-S vaccinee samples was lower than that of sera obtained from mRNA vaccinees. This led us to calculate ratios between binding and neutralizing antibody titers. Samples from NDV-HXP-S vaccinees had binding to neutralizing activity ratios that were lower than those of BNT162b2 sera, suggesting that NDV-HXP-S vaccination elicits a high proportion of neutralizing antibodies and low non-neutralizing antibody titers. Further analysis showed that, in contrast to mRNA vaccination, which induces strong antibody titers to the receptor binding domain (RBD), the N-terminal domain, and the S2 domain, NDV-HXP-S vaccination induced an RBD-focused antibody response with little reactivity to S2. This finding may explain the high proportion of neutralizing antibodies. In conclusion, vaccination with inactivated NDV-HXP-S induces a high proportion of neutralizing antibodies and absolute neutralizing antibody titers that are comparable to those elicited by mRNA vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USA.
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
- Department of Pediatrics, Centers for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Emory University, Atlanta, GA 30329, USA.
- Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
- Department of Pediatrics, University of Washington, Seattle, WA 98109, USA.
- PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA.
ORCID-Profile: Juan Manuel Carreño, Ariel Raskin, Gagandeep Singh, Johnstone Tcheou, Hisaaki Kawabata, Charles Gleason, Vladimir Vigdorovich, Irene González Domínguez, Jose Luis Martinez, Stefan Slamanig, D Noah Sather, Sant Muangnoicharoen, Punnee Pitisuttithum, Jens Wrammert, Mehul S Suthar, Weina Sun, Peter Palese, Adolfo García-Sastre, Viviana Simon, Florian Krammer
Förderung
- NIAID NIH HHS
Zitieren
APA
Carreño, J. M., Raskin, A., Singh, G., Tcheou, J., Kawabata, H., Gleason, C., Srivastava, K., Vigdorovich, V., Dambrauskas, N., Gupta, S. L., González Domínguez, I., Martinez, J. L., Slamanig, S., Sather, D. N., Raghunandan, R., Wirachwong, P., Muangnoicharoen, S., Pitisuttithum, P., Wrammert, J., …, & Krammer, F. (2023). An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abo2847
Vancouver
Carreño JM, Raskin A, Singh G, Tcheou J, Kawabata H, Gleason C, et al. An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination. Science Translational Medicine. 2023. doi:10.1126/scitranslmed.abo2847
BibTeX
@article{Carreo2023,
author = {Carreño, Juan Manuel and Raskin, Ariel and Singh, Gagandeep and Tcheou, Johnstone and Kawabata, Hisaaki and Gleason, Charles and Srivastava, Komal and Vigdorovich, Vladimir and Dambrauskas, Nicholas and Gupta, Sneh Lata and González Domínguez, Irene and Martinez, Jose Luis and Slamanig, Stefan and Sather, D Noah and Raghunandan, Rama and Wirachwong, Ponthip and Muangnoicharoen, Sant and Pitisuttithum, Punnee and Wrammert, Jens and Suthar, Mehul S and Sun, Weina and Palese, Peter and García-Sastre, Adolfo and Simon, Viviana and Krammer, Florian},
title = {An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination},
journal = {Science Translational Medicine},
year = {2023},
doi = {10.1126/scitranslmed.abo2847}
}
EUVIMED